Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19

NCT05132972 is registered in ClinicalTrials.gov with Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia as lead sponsor.

NCT NCT05132972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05132972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19
Lead sponsor
Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 17, 2021
Completion date
November 30, 2021
Enrollment
42 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19